Efthymios Deliargyris
Chief Tech/Sci/R&D Officer chez CYTOSORBENTS CORPORATION
Fortune : 388 961 $ au 31/03/2024
Profil
Efthymios N.
Deliargyris is currently the Chief Medical Officer at CytoSorbents Corp.
He previously held the same position at PLx Pharma, Inc. from 2018 to 2020.
Prior to that, he was the Director of Cardiology and Interventional Cardiology at Athens Medical Center SA from 2004 to 2010, and an Assistant Professor at Wake Forest University from 2001 to 2004.
Deliargyris earned a doctorate degree from the National & Kapodistrian University of Athens.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CYTOSORBENTS CORPORATION
0,78% | 02/04/2024 | 409 433 ( 0,78% ) | 388 961 $ | 31/03/2024 |
Postes actifs de Efthymios Deliargyris
| Sociétés | Poste | Début |
|---|---|---|
| CYTOSORBENTS CORPORATION | Chief Tech/Sci/R&D Officer | 01/05/2020 |
Anciens postes connus de Efthymios Deliargyris
| Sociétés | Poste | Fin |
|---|---|---|
| PLX PHARMA WINDDOWN CORP. | Chief Tech/Sci/R&D Officer | 30/04/2020 |
| ATHENS MEDICAL C.S.A. | Corporate Officer/Principal | 01/01/2010 |
| Wake Forest University | Corporate Officer/Principal | 01/01/2004 |
Formation de Efthymios Deliargyris
| National & Kapodistrian University of Athens | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ATHENS MEDICAL C.S.A. | Health Services |
| Entreprise privées | 2 |
|---|---|
| CytoSorbents Corp. | |
PLx Pharma, Inc.
 PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE. | Health Technology |
